KIT and gastrointestinal stromal tumor: Overall, our findings highlight the need for the molecular re-evaluation of GIST at disease progression and support the exploration of CIK cellular immunotherapy in clinical studies for patients with TKI-resistant, KIT/PDGFRA wild type GIST.